Company profile

Ticker
PKI
Exchange
CEO
Robert F. Friel
Employees
Incorporated
Location
Fiscal year end
Former names
Eg&g Inc
SEC CIK
IRS number
42052042

PKI stock data

(
)

Calendar

12 May 20
6 Aug 20
29 Dec 20

News

Company financial data Financial data

Quarter (USD) Apr 20 Dec 19 Sep 19 Jun 19
Revenue 652.4M 805.5M 706.92M 722.52M
Net income 33.67M 64.5M 58.56M 69.09M
Diluted EPS 0.3 0.58 0.52 0.62
Net profit margin 5.16% 8.01% 8.28% 9.56%
Operating income 44.68M 138.25M 78.66M 91.74M
Net change in cash 3.27M -201.09M 242.95M 15.76M
Cash on hand 195.15M 191.88M 392.97M 150.02M
Cost of revenue 344.37M 364.65M 374.72M
Annual (USD) Dec 19 Dec 18 Dec 17 Dec 14
Revenue 2.88B 2.78B 2.26B 2.24B
Net income 227.56M 237.93M 292.63M 157.78M
Diluted EPS 2.04 2.13 2.64 1.39
Net profit margin 7.89% 8.56% 12.97% 7.05%
Operating income 361.97M 323.88M 295.62M 165.01M
Net change in cash 28.77M -39.02M 27.31M 0
Cash on hand 191.88M 163.11M 202.13M 174.82M
Cost of revenue 1.44B 475.27M 427.27M

Financial data from PerkinElmer earnings reports

Date Owner Security Transaction Code 10b5-1 $Price #Shares $Value #Remaining
31 Jul 20 Goldberg Joel S Common Stock Sell Dispose S Yes 118.34 7,451 881.75K 71,792
31 Jul 20 Goldberg Joel S Common Stock Sell Dispose S Yes 117.6 15,936 1.87M 79,243
31 Jul 20 Goldberg Joel S Common Stock Option exercise Aquire M No 43.01 23,387 1.01M 95,179
31 Jul 20 Goldberg Joel S NQ Stock Option Common Stock Option exercise Dispose M No 43.01 23,387 1.01M 0
29 Jul 20 Okun Andrew Common Stock Sell Dispose S Yes 120 6,699 803.88K 10,310
29 Jul 20 Okun Andrew Common Stock Option exercise Aquire M No 52.65 4,699 247.4K 17,009
29 Jul 20 Okun Andrew NQ Stock Option Common Stock Option exercise Dispose M No 52.65 4,699 247.4K 0
15 Jun 20 Tereau Daniel R Common Stock Sell Dispose S Yes 95.22 5,452 519.14K 7,427
15 Jun 20 Tereau Daniel R Common Stock Option exercise Aquire M No 43.735 3,242 141.79K 12,879
15 Jun 20 Tereau Daniel R NQ Stock Option Common Stock Option exercise Dispose M No 43.735 3,242 141.79K 0
93.4% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 414 423 -2.1%
Opened positions 48 61 -21.3%
Closed positions 57 52 +9.6%
Increased positions 126 148 -14.9%
Reduced positions 158 124 +27.4%
13F shares
Current Prev Q Change
Total value 474.26B 596.77B -20.5%
Total shares 104.08M 107.79M -3.4%
Total puts 54.7K 13.14K +316.3%
Total calls 55.3K 177.8K -68.9%
Total put/call ratio 1.0 0.1 +1238.4%
Largest owners
Shares Value Change
N Price T Rowe Associates 18.05M $1.36B -9.2%
Vanguard 12.56M $945.55M +2.4%
Capital Research Global Investors 11.81M $889.19M -0.4%
BLK BlackRock 7.14M $537.8M +0.7%
JHG Janus Henderson 6.49M $488.87M -0.6%
Select Equity 5.82M $438.48B +2.4%
Massachusetts Financial Services 4.89M $367.92M -1.4%
STT State Street 4.5M $338.39M +1.5%
King Luther Capital Management 2.43M $183.18M -3.6%
Primecap Management 2.4M $180.83M -6.0%
Largest transactions
Shares Bought/sold Change
N Price T Rowe Associates 18.05M -1.83M -9.2%
Norges Bank 0 -824.1K EXIT
Citadel Advisors 3.26K -393.39K -99.2%
Artisan Partners Limited Partnership 0 -297.63K EXIT
Vanguard 12.56M +289.01K +2.4%
Echo Street Capital Management 998.51K +277.97K +38.6%
GS Goldman Sachs 775.23K -236.17K -23.4%
Nuveen Asset Management 311.71K -203.27K -39.5%
Alta Capital Management 398.55K +201.72K +102.5%
First Trust Advisors 243.92K +192.41K +373.5%

Financial report summary

?
Risks
  • If the markets into which we sell our products decline or do not grow as anticipated due to a decline in general economic conditions, or there are uncertainties surrounding the approval of government or industrial funding proposals, or there are unfavorable changes in government regulations, we may see an adverse effect on the results of our business operations.
  • Our growth is subject to global economic and political conditions, and operational disruptions at our facilities.
  • If we do not introduce new products in a timely manner, we may lose market share and be unable to achieve revenue growth targets.
  • We may not be able to successfully execute acquisitions or divestitures, license technologies, integrate acquired businesses or licensed technologies into our existing businesses, or make acquired businesses or licensed technologies profitable.
  • We may not be successful in adequately protecting our intellectual property.
  • If we are unable to renew our licenses or otherwise lose our licensed rights, we may have to stop selling products or we may lose competitive advantage.
  • If we do not compete effectively, our business will be harmed.
  • Our quarterly operating results could be subject to significant fluctuation, and we may not be able to adjust our operations to effectively address changes we do not anticipate, which could increase the volatility of our stock price and potentially cause losses to our shareholders.
  • A significant disruption in third-party package delivery and import/export services, or significant increases in prices for those services, could interfere with our ability to ship products, increase our costs and lower our profitability.
  • Disruptions in the supply of raw materials, certain key components and other goods from our limited or single source suppliers could have an adverse effect on the results of our business operations, and could damage our relationships with customers.
  • The manufacture and sale of products and services may expose us to product and other liability claims for which we could have substantial liability.
  • If we fail to maintain satisfactory compliance with the regulations of the United States Food and Drug Administration and other governmental agencies in the United States and abroad, we may be forced to recall products and cease their manufacture and distribution, and we could be subject to civil, criminal or monetary penalties.
  • Changes in governmental regulations may reduce demand for our products or increase our expenses.
  • The healthcare industry is highly regulated and if we fail to comply with its extensive system of laws and regulations, we could suffer fines and penalties or be required to make significant changes to our operations which could have a significant adverse effect on the results of our business operations.
  • Economic, political and other risks associated with foreign operations could adversely affect our international sales and profitability.
  • If we do not retain our key personnel, our ability to execute our business strategy will be limited.
  • If we experience a significant disruption in, or breach in security of, our information technology systems or those of our customers, suppliers or other third parties, or cybercrime, resulting in inappropriate access to or inadvertent transfer of information or assets, or if we fail to implement new systems, software and technologies successfully, our business could be adversely affected.
  • We have a substantial amount of outstanding debt, which could impact our ability to obtain future financing and limit our ability to make other expenditures in the conduct of our business.
  • Restrictions in our senior unsecured revolving credit facility and other debt instruments may limit our activities.
  • Discontinuation, reform, or replacement of LIBOR may adversely affect our variable rate debt.
  • Our share price will fluctuate.
Management Discussion
  • Revenue for fiscal year 2019 was $2,883.7 million, as compared to $2,778.0 million for fiscal year 2018, an increase of $105.7 million, or 4%, which includes an approximate 1% increase in revenue attributable to acquisitions and divestitures and a
  • 2% decrease in revenue attributable to changes in foreign exchange rates. The analysis in the remainder of this paragraph compares segment revenue for fiscal year 2019 as compared to fiscal year 2018 and includes the effect of foreign exchange rate fluctuations, and acquisitions and divestitures. The total increase in revenue reflects an increase in our Diagnostics segment revenue of $52.7 million, or 5%, due to growth in our reproductive health and immunodiagnostics businesses partially offset by unfavorable changes in foreign exchange rates. Our Discovery & Analytical Solutions segment revenue increased by $53.0 million, or 3%, due to an increase of $42.5 million from our life sciences market revenue and an increase of $10.4 million from our applied markets revenue, partially offset by unfavorable changes in foreign exchange rates. As a result of adjustments to deferred revenue related to certain acquisitions required by business combination rules, we did not recognize $0.8 million of revenue primarily related to our Diagnostics segment for each of fiscal years 2019 and 2018 that otherwise would have been recorded by the acquired businesses during each of the respective periods.
  • Cost of revenue for fiscal year 2019 was $1,487.6 million, as compared to $1,437.1 million for fiscal year 2018, an increase of approximately $50.6 million, or 4%. As a percentage of revenue, cost of revenue decreased to 51.6% in fiscal year 2019 from 51.7% in fiscal year 2018, resulting in an increase in gross margin of approximately 14 basis points to 48.4% in fiscal year 2019 from 48.3% in fiscal year 2018. Amortization of intangible assets increased and was $61.4 million for fiscal year 2019, as compared to $46.2 million for fiscal year 2018. Stock-based compensation expense was $1.6 million for fiscal year 2019, as compared to $1.5 million for fiscal year 2018. The amortization of purchase accounting adjustments to record the inventory from certain acquisitions added an incremental expense of $21.6 million for fiscal year 2019, as compared to $19.3 million for fiscal year 2018. Acquisition and divestiture-related expenses, contingent consideration and other costs were minimal for fiscal year 2019, as compared to an incremental expense of $0.1 million for fiscal year 2018. In addition to the factors noted above, the overall increase in gross margin primarily the result of mix, price and improved manufacturing and services productivity.
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: absenteeism, accessibility, Aid, beneficial, closure, complexity, cybersecurity, disease, distancing, distraction, extra, franchise, impeding, imposed, intraperiod, investor, labor, methodology, newly, ownership, pandemic, refinance, refined, relocating, relocation, remote, remotely, Shandong, Simplifying, situation, slowdown, social, travel, ultimate, ultimately, unknown, withdrew
Removed: account, broad, clarification, commenced, comparative, construction, correct, criteria, depending, depreciated, derecognized, Error, EUROIMMUN, expand, explicitly, extend, February, genomic, grew, identical, identified, implicit, improved, intention, invested, involvement, leasing, lessee, lessor, nonlease, notified, occupying, October, opening, optional, owner, pattern, plant, predominant, principle, Profit, reimbursed, remove, removed, rental, representing, reversed, ROU, separately, set, sixteen, stronger, Supplemental, understand, withdraw, withdrawing

Patents

GRANT
Utility
Storage container for liquids
28 Jul 20
Inventors: Lars Koschinat
GRANT
Utility
Diagnosis of a neuroautoimmune disease
28 Jul 20
The present invention relates to a method for diagnosing a disease comprising the step detecting in a sample comprising antibodies from a patient an autoantibody binding to a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, a polypeptide comprising a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, or a variant thereof, a use of said polypeptide for the diagnosis of a disease, an autoantibody binding to a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, a use of the autoantibody for the diagnosis of a disease, a method for isolating an autoantibody binding to a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, a pharmaceutical composition or medical device comprising said polypeptide according to the present invention, a kit for the diagnosis of a disease comprising said polypeptide or said medical device and a use of said polypeptide or autoantibody for the manufacture of a kit or medical device.
GRANT
Utility
Ion flow guide devices and methods
28 Jul 20
Certain configurations of devices are described herein that include DC multipoles that are effective to direct ions.
APP
Utility
Hollow Polymer Fiber Optic System for Single Analyte and Multiplexed Analyte Detection
23 Jul 20
Presented herein are methods, systems, and apparatus for single analyte detection or multiplexed analyte detection based on amplified luminescent proximity homogeneous assay (“alpha”) technology, but using hollow polymer fiber optics doped with ‘acceptor bead’ dye (e.g., thioxene, anthracene, rubrene, and/or lanthanide chelates) or ‘donor bead’ dye (e.g., phthalocyanine) that carry a signal generated by the dopant via singlet oxygen channeling.
APP
Utility
Antigen detection of Trichinella
23 Jul 20
Trichinella can be detected in a tissue extract sample.